

Local Action Plan: NLCA State of the Nation Report 2023							
The provider should complete the following details to allow for ease of review							
Audit title & aim:	National Lung Cancer Audit (NLCA)						
	To assess the process of care and its outcomes in patients with lung						
	cancer						
NHS organisation:							
Audit lead:							
Action plan lead:							

When making your action plan, make sure to keep the objectives SMART – Specific, Measurable, Assignable, Realistic, Time-related

Key 1 (for the action status)

- 1. Awaiting plan of action
- 2. Action in progress
- 3. Action fully implemented
- 4. No plan to action recommendation (state reason)
- **5.** Other (provide information)

Key 2 (for the action priority)

High: requires urgent attention (local audit) Medium: requires prompt action (consider local audit) Low: requires no immediate action (or local audit)

			Action activities			
No.	Recommendation	Action required?	Responsible	Agreed	Status	Priority
			individual(s)	deadline	(Key 1)	(Key 2)
R1	Aim to achieve high levels of	Suggested actions:				
	data completeness in the cancer					

	registration datasets, particularly the Rapid Cancer Registration Dataset and COSD in England. - Completeness should be at least 95% for performance status (PS), ethnicity and disease stage, and at least 90% for "trust first seen", route to diagnosis, seen by a LCNS at diagnosis and smoking status (to highlight inequalities and inform future strategies).	 Appoint a clinical data lead with protected time for reviewing and checking the team's data returns and for championing improvements in the completeness of key data items. Review the completeness of key data items including TNM staging information, lung cancer nurse specialist, smoking status and Performance status submitted to the National Cancer Registration and Analysis Service Raise the profile of data completeness across the wider multidisciplinary team (MDT) at governance meetings or by sharing data. Feedback monthly data quality reports to the wider MDT. Integrate data collection into MDT meetings with the aim of achieving 90% completeness of key data items
R2	Ensure at least 85% of patients with stage I/II PS 0–2 NSCLC undergo curative-intent treatment in line with NICE guidance	Suggested actions: Review own MDT performance of treatment of NSCLC stage I/II Share results at MDT to highlight this target Feedback monthly data reports to the wider MDT Identify barriers to curative-intent treatment
R3	Ensure at least 70% of patients with NSCLC stage IIIB-IV and PS 0-1 receive systemic anti-cancer therapy in line with NICE guidance.	Suggested actions: Review own MDT performance of treatment of NSCLC Feedback monthly data reports to the wider MDT Identify barriers to SATC
R4	Ensure at least 90% of lung cancer patients are seen by a	Suggested actions: • • Appoint a clinical data lead with protected time for reviewing and checking the team's data returns and

	lung cancer clinical nurse specialist at diagnosis.	 for championing improvements in the completeness of key data items Improve recording of attendance of health care professionals at clinics, MDTs etc 		
R5	Resource lung cancer MDTs according to the commissioning guidance set out by the Lung Cancer Clinical Expert Group, and update the guidance to reflect current best practice.	 Suggested actions: MDTs to compare current resources / workforce to service specification set out by Clinical Expert Group. Use NLCA data and this comparison to build business cases to aid compliance with service specification 		

The NLCA welcome your feedback on this quality improvement template to be used in conjunction with the NLCA State of the Nation Report provider level results and quality improvement resources presented on our website.

Please contact the NLCA team <u>nlca@rcseng.ac.uk</u> if you have any questions related to your results, data collection or service improvement.

References

- 1. NLCA State of the Nation Report 2023 <u>www.lungcanceraudit.org.uk</u>
- 2. NICE Guidelines Lung Cancer Lung cancer: diagnosis and management (2019) NICE guideline [NG122] <u>Treatment | Lung cancer: diagnosis and management |</u> <u>Guidance | NICE</u>